Trial reportFrontiers in endocrinology2026
Serum anti-Müllerian hormone response to pyrroloquinoline quinone supplementation in healthy women: no overall change and exploratory subgroup findings.
Trial report in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Oocyte maturation requires substantial ATP, and the resulting oxidative stress may impair follicular development. Pyrroloquinoline quinone (PQQ), an antioxidant compound, protects mitochondria and promotes follicular development in animal models; however, its effects on human ovarian function remain unclear. Methods: This single-arm, open-label study prospectively evaluated the effects of oral PQQ supplementation on ovarian reserve and related clinical and biochemical outcomes. The primary outcome was serum anti-Müllerian hormone (AMH). Secondary outcomes included luteinizing hormone, follicle-stimulating hormone, estradiol, biological antioxidant potential, reactive oxygen metabolites-derived compounds (d-ROMs), and Menstrual Distress Questionnaire (MDQ) scores. Fifty healthy women aged 25-42 years with regular menstrual cycles and baseline serum AMH levels of 0.5 ≤ AMH < 3.0 ng/mL received 20 mg/day of PQQ for 90 ± 10 days. Blood samples were collected on menstrual cycle days 1-7 before and after supplementation. Exploratory subgroup analyses were performed using combined stratification by age and baseline AMH. Results: Analyses were conducted in the per-protocol set ( Conclusion: PQQ supplementation did not alter AMH levels in the overall cohort. Subgroup findings were inconsistent and should be interpreted cautiously given the small sample sizes and absence of a control group. These exploratory results do not permit conclusions regarding clinical efficacy. Larger, placebo-controlled trials with imaging-based and clinical reproductive endpoints are needed to determine whether PQQ has measurable effects on ovarian biology. Clinical trial registration: https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056669, identifier UMIN000049793.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.